» Articles » PMID: 1268491

Impaired Lignocaine Metabolism in Patients with Myocardial Infarction and Cardiac Failure

Overview
Journal Br Med J
Specialty General Medicine
Date 1976 Apr 17
PMID 1268491
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Plasma concentrations of lignocaine were measured during and after infusion of lignocaine at 1.4 mg/min for 36-46 hours in 12 patients with myocardial infarction and one patient with cardiac failure due to uncontrolled ventricular tachycardia. In six patients without cardiac failure the plasma concentrations of lignocaine rose progressively during the infusion and the mean lignocaine half life was 4.3 hours compared with 1.4 hours in healthy subjects. Mean plasma lignocaine concentrations were significantly higher in seven patients with cardiac failure, and concentrations also rose during the infusion and the half life was considerably prolonged to 10.2 hours. Lignocaine concentrations rose rapidly to toxic levels when cardiogenic shock developed in one patient and did not fall when the infusion was stopped. The mean plasma antipyrine half life was moderately prolonged (19.4 hours) in a larger group of patients with myocardial infarction and cardiac failure but returned to normal during convalescence (13.2 hours). The metabolism of lignocaine is grossly abnormal in patients with cardiac failure and cardiogenic shock after myocardial infarction.

Citing Articles

Population Pharmacokinetics of Intravenous Lidocaine in Adults: A Systematic Review.

Foong K, Chaw S, Lo Y, Loh P Clin Pharmacokinet. 2024; 63(5):623-643.

PMID: 38703307 DOI: 10.1007/s40262-024-01373-4.


The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: a critical appraisal of the evidence.

Mangoni A, Jarmuzewska E Br J Clin Pharmacol. 2018; 85(1):20-36.

PMID: 30194701 PMC: 6303202. DOI: 10.1111/bcp.13760.


Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously).

Ogawa R, Stachnik J, Echizen H Clin Pharmacokinet. 2013; 52(3):169-85.

PMID: 23344981 DOI: 10.1007/s40262-012-0029-2.


Drug disposition in pathophysiological conditions.

Gandhi A, Moorthy B, Ghose R Curr Drug Metab. 2012; 13(9):1327-44.

PMID: 22746301 PMC: 3937312. DOI: 10.2174/138920012803341302.


A population pharmacokinetic model of epidural lidocaine in geriatric patients: effects of low-dose dopamine.

Kwa A, Sprung J, Van Guilder M, Jelliffe R Ther Drug Monit. 2008; 30(3):379-89.

PMID: 18520611 PMC: 2724678. DOI: 10.1097/FTD.0b013e3181778fa3.


References
1.
Tokola O, Pelkonen O, KARKI N, Luoma P . Hepatic drug-oxidizing enzyme systems and urinary D-glucaric acid excretion in patients with congestive heart failure. Br J Clin Pharmacol. 1975; 2(5):429-36. PMC: 1402618. DOI: 10.1111/j.1365-2125.1975.tb00552.x. View

2.
Ryden L, Waldenstrom A, Winsnes Y, ORTENGREN B . Blood levels of lidocaine after various infusion rates in patients with acute myocardial infarction. Am Heart J. 1975; 89(4):470-3. DOI: 10.1016/0002-8703(75)90153-2. View

3.
Strong J, Mayfield D, Atkinson Jr A, BURRIS B, RAYMON F, WEBSTER Jr L . Pharmacological activity, metabolism, and pharmacokinetics of glycinexylidide. Clin Pharmacol Ther. 1975; 17(2):184-94. DOI: 10.1002/cpt1975172184. View

4.
Halkin H, Meffin P, Melmon K, Rowland M . Influence of congestive heart failure on blood vessels of lidocaine and its active monodeethylated metabolite. Clin Pharmacol Ther. 1975; 17(6):669-76. DOI: 10.1002/cpt1975176669. View

5.
Talbot R, Nimmo J, Julian D, Clark R, Neilson J, Prescott L . Treatment of ventricular arrhythmias with mexiletine (Kö 1173). Lancet. 1973; 2(7826):399-404. DOI: 10.1016/s0140-6736(73)92270-8. View